Pancreatic cancer, notorious for its dismal prognosis and resistance to conventional treatments, has long been studied primarily with a focus on cancer cells and commonly recognized components of the tumor microenvironment such as immune cells, vasculature, and fibroblasts. However, the nervous system’s involvement has remained largely enigmatic. The new study brings sympathetic nerves—components of the autonomic nervous system responsible for the body’s “fight or flight” response—into sharp scientific focus, showing that these nerves physically infiltrate pancreatic tumors and engage in biochemical crosstalk with cancer cells and supportive stromal fibroblasts.

The sympathetic nervous system exerts its influence through the release of neurotransmitters like norepinephrine, which bind to receptors on both cancer cells and fibroblasts. This signaling cascade appears to foster a tumor-promoting milieu by influencing multiple cellular pathways that enhance tumor cell proliferation, survival, and extracellular matrix remodeling. The latter process is critical as activated fibroblasts modify the structural architecture around the tumor, facilitating invasive and metastatic behavior.

A key technical challenge addressed by the research team was the difficulty in detecting the nerve fibers within the tumor due to their small and fragmented nature and the predominant location of nerve cell bodies outside the tumor mass. To circumvent these limitations, researchers devised novel molecular marker panels capable of identifying sympathetic nerves and established genetically engineered mouse models with selective ablation of sympathetic innervation in the pancreas. This innovative approach uncovered that nerve removal resulted in tumor size reduction; strikingly, this effect was observed exclusively in female mice, underscoring a sex-dependent influence on tumor progression.

The sex specificity suggested by the study introduces a fascinating layer of complexity implicating sex hormones as modulators of neural-tumor interactions. Estrogen and other hormones may influence the expression of receptors or signaling pathways in nerves or fibroblasts, transforming how sympathetic signals impact the cancer ecosystem. This revelation opens new investigative pathways into hormonal modulation as a therapeutic angle and stresses the importance of considering sex as a biological variable in cancer research.

Beyond the experimental work, correlational analyses in human pancreatic cancer patients revealed that genes associated with sympathetic nerve activity correlate with poorer survival outcomes. This finding fortifies the translational relevance of the study and highlights the sympathetic nervous system as a clinical biomarker candidate and a potential target for therapy.

Current cancer therapeutics have predominantly ignored the nervous system as a direct target, but this research advocates for a paradigm shift. There is burgeoning interest in repurposing existing pharmacological agents—such as beta-adrenergic blockers, commonly used for cardiovascular diseases—to attenuate the neurogenic signals that drive tumor progression. Moreover, the recent advent of neural stimulation devices for neurological and psychiatric disorders raises the intriguing possibility of neuromodulation as a complementary strategy in oncology.

The study, published in JCI Insight, exemplifies the burgeoning interdisciplinary field of cancer neuroscience. Its core message is profound: tumors reside in an intricate ecosystem where multiple body systems communicate and influence oncogenesis. The dialogue between nerves and fibroblasts within pancreatic tumors highlights the need to approach cancer treatment not only on the cellular or molecular level but also from a system biology perspective that integrates neural, hormonal, and immune inputs.

Investigators at OHSU are now extending these findings to explore the mechanisms by which nerve injury and matrix remodeling orchestrated by fibroblasts contribute to tumor aggressiveness. Understanding the detailed signaling pathways and receptor interactions in this neural-stromal crosstalk holds promise for identifying novel molecular targets.

This novel conceptual framework challenges the entrenched dogma in oncology and opens avenues for the design of innovative therapeutics. By regulating nerve-cancer cell interactions and disrupting pathological communication channels, there is hope to impede pancreatic tumor growth more effectively.

In summary, this pioneering research not only broadens our understanding of the tumor microenvironment but also reveals how the nervous system’s role can be pivotal in malignant progression. It signals the need for concerted multidisciplinary efforts to translate these insights into clinically viable interventions that can ultimately improve survival outcomes in one of the deadliest forms of cancer.

Subject of Research: Sympathetic nerve involvement in pancreatic cancer tumor microenvironment
Article Title: Sympathetic nerve–fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer
Web References: https://insight.jci.org/articles/view/192814
References: Published in the journal JCI Insight, DOI: 10.1172/jci.insight.192814
Keywords: Pancreatic cancer, sympathetic nerves, cancer-associated fibroblasts, tumor microenvironment, neural-tumor crosstalk, nerve ablation, sex differences in cancer, beta blockers, nerve injury, matrix remodeling, tumor progression, cancer neuroscience

Cancer cachexia is not simply a result of reduced food intake but is a multifactorial condition involving various biological mechanisms. It leads to profound metabolic dysregulation and is linked to increased morbidity and mortality. The research team sought to dissect the molecular crosstalk between CAFs and cancer cells, specifically how this interaction contributes to the cachectic phenotype. Their hypothesis centered on CXCL5, suggesting it as a crucial player in this vicious cycle, orchestrating the inflammatory response and metabolic changes seen in cachexia.

In their experimental design, the researchers employed a combination of in vitro and in vivo models that mimicked the cachectic environment. These models allowed them to investigate the secretion of CXCL5 by CAFs and its subsequent effects on cancer cell behavior. The results revealed that elevated levels of CXCL5 significantly contributed to the cachectic state, promoting a pro-inflammatory milieu that facilitated muscle breakdown and fat depletion.

Further analysis showed that CXCL5 not only influenced cancer cells but also exerted effects on the surrounding microenvironment, shaping the behavior of CAFs. This reciprocal relationship marked a critical finding, underscoring how CAFs can perpetuate a cycle of inflammation and cachexia through CXCL5 signaling. The disruption of this signaling axis appears to be a promising therapeutic avenue, affording researchers a potential target to alleviate cachexia symptoms.

The study delves into the mechanisms at play, highlighting the role of the CXCL5/CXCR2 axis in fostering an environment conducive to tumor progression and cachexia. Cancer cells respond to CXCL5 by upregulating factors instrumental in promoting inflammation and catabolism. The modulation of this pathway thus stands out as a pivotal strategy to curtail the adverse effects experienced by cachectic patients.

Transitioning from basic research to clinical implications, the insights gained from this study underscore a critical need for novel therapeutic interventions for cachexia. The potential for CXCL5 neutralization to disrupt the harmful crosstalk between CAFs and cancer cells suggests an innovative strategy to combat this syndrome. Therapies that target this specific interaction could enhance the quality of life for patients suffering from cachexia, while also improving their overall cancer treatment outcomes.

This research also sets the stage for further exploration into other chemokines and cytokines that may play a role in cancer cachexia. By broadening the scope of investigation to include a wider array of factors, scientists can paint a more comprehensive picture of the biological underpinnings of this condition. Understanding the interplay of different signaling pathways could yield new insights and therapeutic targets, potentially unlocking more effective treatment modalities.

As the scientific community rallies around the challenge of cancer cachexia, this study contributes essential knowledge to the discourse. The collaboration between different fields of research, including oncology, immunology, and metabolism, will be critical in addressing the multi-faceted nature of cachexia. It highlights the importance of continued research efforts aimed at understanding the intersections of cancer biology and systemic metabolic alterations.

Future studies will need to validate the findings in larger cohorts and explore the efficacy of CXCL5 neutralization in clinical settings. With the rapid advancement of therapeutic approaches aimed at chemokine signaling, the possibilities for innovation in treating cachexia seem promising. The objective remains clear: to develop strategies that not only improve survival rates but also enhance the quality of life for cancer patients battling the burdens of cachexia.

In conclusion, the study led by Kim and colleagues offers compelling evidence that neutralizing CXCL5 may be a breakthrough strategy to alleviate cancer cachexia. By unraveling the complexities of CAF-cancer cell interactions, this research paves the way for targeted interventions that could alter the trajectory of cachexia management. As the field advances, the focus on this critical aspect of cancer care will undoubtedly remain pivotal, influencing both research directions and clinical practices aimed at empowering patients in their fight against cancer.

The implications of this research extend beyond immediate therapeutic applications; they call for a paradigm shift in how we perceive cancer cachexia. No longer viewed simply as a byproduct of cancer, cachexia is emerging as a significant factor that warrants focused attention. By embracing a holistic perspective that incorporates the multifaceted interactions at play, healthcare providers can better equip themselves to address the diverse needs of cancer patients grappling with this complex syndrome.

Ultimately, the journey to understanding cancer cachexia is just beginning. As researchers like Kim and their colleagues continue to investigate the intricate web of signaling pathways, the hope is that innovative therapies will emerge. With dedicated research and collaborative efforts, the vision of alleviating cancer cachexia and improving patient outcomes can become a reality.

Subject of Research: CXCL5 and its role in cancer cachexia

Article Title: CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

Article References:

Kim, HJ., Kim, SW., Kim, JH. et al. CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.
J Biomed Sci 32, 107 (2025). https://doi.org/10.1186/s12929-025-01192-0

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12929-025-01192-0

Keywords: Cancer cachexia, CXCL5, CAF-cancer cell interactions, inflammation, therapeutic strategies.